Research over the last several years has found that in some patients with lupus, there is increased production of interferon-alpha. This molecule activates some genes which control the production of inflammatory proteins. This so-called “interferon signature” has been considered, therefore, a potentially modifiable pathway in the efforts to treat lupus. Rontalizumab is such a drug and may benefit people with lupus.